Increasing incidence of Clostridium difficile ribotype 001 associated with severe course of the infection and previous fluoroquinolone use in the Czech Republic, 2015
Language English Country Germany Media print-electronic
Document type Journal Article
PubMed
28681203
DOI
10.1007/s10096-017-3055-z
PII: 10.1007/s10096-017-3055-z
Knihovny.cz E-resources
- Keywords
- CDI surveillance, Capillary electrophoresis ribotyping, Clostridium difficile, Clostridium difficile infection, Fluoroquinolones, Toxin genes,
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Drug Resistance, Bacterial physiology MeSH
- Clostridioides difficile classification genetics isolation & purification MeSH
- Fluoroquinolones therapeutic use MeSH
- Cross Infection epidemiology microbiology MeSH
- Humans MeSH
- Hospitals MeSH
- Enterocolitis, Pseudomembranous drug therapy epidemiology microbiology MeSH
- Ribotyping MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic epidemiology MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Fluoroquinolones MeSH
The aim of the study was to provide an update on the epidemiology of C. difficile infection (CDI) in a representative number of hospitals within the Czech Republic in 2015. In 2015, twenty-eight Czech hospitals were invited to participate in a CDI study. Laboratories sent the first 20 consecutive C. difficile isolates for characterization by capillary-electrophoresis (CE) ribotyping and the presence of toxin genes and collected patient data on previous hospitalization, antibiotic treatment, the number of CDI episodes and the course of CDI. The mean incidence of CDI was 5.2 [95% CI 4.2-6.2] cases per 10,000 patient-bed days in 27 hospitals in 2015. Of 490 C. difficile isolates, the prevalent PCR ribotypes (RTs) were 001 (n = 164, 33.5%) and 176 (n = 125, 25.5%) followed by 014 (n = 37, 7.6%), 012 (n = 17, 3.5%), 020 (n = 16, 3.3%), 017 (n = 14, 2.9%) and 002 (n = 11, 2.2%). A severe course of CDI was reported in 104 cases (21.2%) with significant association with RT001 infection (p = 0.03). CDI recurrence was 10.8% (n = 53). The previous use of fluoroquinolones was associated with RTs 001 and 176 CDIs (p = 0.046 and p = 0.041). We observed a persistence of RTs 001 and 176 CDIs in the Czech Republic that was associated with the previous use of fluoroquinolones. This highlights the need for a reduction in fluoroquinolone use in Czech hospital settings.
See more in PubMed
Clin Microbiol Infect. 2007 Nov;13(11):1048-57 PubMed
Ann Clin Microbiol Antimicrob. 2015 Dec 23;14:55 PubMed
J Med Microbiol. 2016 Oct;65(10 ):1158-1163 PubMed
Euro Surveill. 2016 Jul 21;21(29): PubMed
Euro Surveill. 2015;20(38):null PubMed
Clin Microbiol Infect. 2003 Oct;9(10):989-96 PubMed
Folia Microbiol (Praha). 2014 Nov;59(6):523-6 PubMed
Clin Microbiol Infect. 2016 Aug;22 Suppl 4:S63-81 PubMed
Infect Genet Evol. 2012 Oct;12(7):1577-85 PubMed
Clin Microbiol Infect. 2015 Mar;21(3):248.e9-248.e16 PubMed
Lancet Infect Dis. 2013 Nov;13(11):936-45 PubMed
J Clin Microbiol. 1999 Feb;37(2):461-3 PubMed
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26 PubMed
J Med Microbiol. 2008 Nov;57(Pt 11):1377-82 PubMed
Anaerobe. 2015 Dec;36:88-90 PubMed
Lancet. 2011 Jan 1;377(9759):63-73 PubMed
Euro Surveill. 2009 Nov 12;14(45):null PubMed
Klin Mikrobiol Infekc Lek. 2014 Jun;20(2):56-66 PubMed
Epidemiol Mikrobiol Imunol. 2015 Jun;64(2):92-7 PubMed
Euro Surveill. 2016 Jul 21;21(29): PubMed
Euro Surveill. 2016 Jul 21;21(29): PubMed
Clin Microbiol Infect. 2008 Nov;14(11):1057-64 PubMed
J Antimicrob Chemother. 2017 Jan;72 (1):1-18 PubMed
Lancet Infect Dis. 2014 Dec;14(12):1208-19 PubMed
Lancet Infect Dis. 2017 Apr;17 (4):411-421 PubMed
Anaerobe. 2016 Dec;42:142-144 PubMed
PLoS One. 2015 Feb 13;10(2):e0118150 PubMed
Anaerobe. 2016 Aug;40:35-40 PubMed
Is shorter also better in the treatment of Clostridioides difficile infection?
